Stockscreener 앱 받기
62.55
2.88%
1.75
시간 외 거래:
62.55
Tarsus Pharmaceuticals Inc 주식(TARS)의 최신 뉴스
Tarsus Pharmaceuticals (NASDAQ: TARS) insider files to sell 12,500 shares - Stock Titan
[144] Tarsus Pharmaceuticals, Inc. SEC Filing - Stock Titan
Tarsus Pharmaceuticals, Inc. Q1 2026 earnings preview - MSN
Is Conference-Spotlighted XDEMVY Adoption Quietly Reshaping the Long-Term Narrative for Tarsus (TARS)? - Sahm
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Strong Longer Term Returns - Sahm
A Look At Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Strength And Perceived Discount - Yahoo Finance
Clearbridge Investments LLC Cuts Stake in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Understanding the Setup: (TARS) and Scalable Risk - Stock Traders Daily
Tarsus Pharmaceuticals (NASDAQ:TARS) Upgraded to Buy at Wall Street Zen - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Autolus Therapeutics (AUTL), Wuxi Biologics (Cayman) (WXIBF) - The Globe and Mail
TARS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
William Blair Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating - Moomoo
Evaluating Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness - Sahm
Tarsus Pharmaceuticals (TARS) Holds Steady Near $59 as Consolidation ContinuesJurik MA - newsline.com
Tarsus Pharmaceuticals (TARS) Holds Steady Near Support as Market Watches Key LevelsPre-Earnings Momentum - newsline.com
Tarsus to Participate in Upcoming Investor Conferences - GlobeNewswire
Tarsus Pharmaceuticals (TARS) Gets a Buy from H.C. Wainwright - The Globe and Mail
The Technical Signals Behind (TARS) That Institutions Follow - Stock Traders Daily
Tarsus Pharmaceuticals (TARS) Shows Resilience Near Support After Moderate DeclineBull Pennant - The Legal Advocate
H.C. Wainwright Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $88 - Moomoo
Tarsus Pharmaceuticals (TARS) Sees Minor Pullback as Traders Eye Support ZoneDeath Cross - newsline.com
Assessing Tarsus Pharmaceuticals (TARS) Valuation After New TP-05 Phase 2b Lyme Disease Trial Update - Sahm
Tarsus Advances TP-05 Lyme Prevention Trial, Setting Up a New Mid-Stage Catalyst for TARS Investors - TipRanks
John Cena hops into the ring to fight demodex blepharitis for Tarsus Pharmaceuticals - Medical Marketing and Media
Tarsus, RxSight Fall Despite Growth Signals - Orange County Business Journal
Precision Trading with Tarsus Pharmaceuticals Inc. (TARS) Risk Zones - Stock Traders Daily
Janus Henderson holds 2.24M shares in Tarsus Pharmaceuticals (TARS) - Stock Titan
Tarsus Q1 Review: Strong Earnings, But Wall Street Wanted A Guidance Raise (NASDAQ:TARS) - Seeking Alpha
Deep Track entities report 3.6M shares in Tarsus (NASDAQ: TARS) - Stock Titan
Did Tarsus’ (TARS) Surge in Q1 Revenue and Narrower Loss Just Shift Its Investment Narrative? - Sahm
Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Tarsus and John Cena Partner to Raise Awareness of Demodex - GlobeNewswire
Number of shareholders of Tarsus Pharmaceuticals, Inc. – NASDAQ:TARS - TradingView
Number of shareholders of Tarsus Pharmaceuticals, Inc. – BX:TARS - TradingView
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Long Term Gains - Yahoo Finance
Is It Time To Reassess Tarsus Pharmaceuticals (TARS) After Its Recent Share Price Swings? - Yahoo Finance
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Pipeline Growth Expectations - Sahm
Lifesci Capital Has Negative Estimate for TARS Q2 Earnings - MarketBeat
What is HC Wainwright's Estimate for TARS Q2 Earnings? - MarketBeat
Tarsus Pharmaceuticals Earnings Call Signals Durable Growth - TipRanks
Vanguard Group Inc. Purchases 127,470 Shares of Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Tarsus reiterates 2026 net product sales guidance of $670M-$700M as XDEMVY posts $145.4M in Q1 sales - MSN
Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $90 - Moomoo
Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100 - Moomoo
LifeSci Capital Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $95 - Moomoo
Prudential subsidiaries hold 1.84M Tarsus shares (NASDAQ: TARS) - Stock Titan
A Quick Look at Today's Ratings for Tarsus Pharmaceuticals(TARS.US), With a Forecast Between $88 to $95 - Moomoo
Tarsus Pharmaceuticals Reports Revenue Increase in Q1 Driven by Xdemvy - VisionMonday.com
Tarsus Pharmaceuticals (TARS) Reports Strong Q1 2026 Earnings Dr - GuruFocus
Three Tarsus conference webcasts are set for May, with replays to follow - Stock Titan
Q1 2026 Tarsus Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q1 2026 Earnings Call Transcript - Insider Monkey
2.60%
0.94%
자본화:
|
볼륨(24시간):